
    
      This is a Phase 2 study designed to evaluate the efficacy and safety of ABT-126 in
      approximately 420 adults with mild to moderate Alzheimer's disease who are taking stable
      doses of acetylcholinesterase inhibitors. Subjects will be randomized to one of two ABT-126
      dose arms or placebo for a 24-week treatment period.
    
  